# ErbB2 Positive Metastatic Breast Cancer

> **NCT01658358** · PHASE1,PHASE2 · TERMINATED · sponsor: **China Medical University Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Lapatinib
- **DRUG:** Lipo-Dox

## Key facts

- **NCT ID:** NCT01658358
- **Lead sponsor:** China Medical University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2013-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01658358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01658358, "ErbB2 Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01658358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*